Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top and bottom lines: revenue was $10.9M vs. $12.7M expected, and Diluted EPS was -$0.38 vs. -$0.29 expected. The 18% YoY revenue growth was fueled by a 62% surge in Neurosurgery Navigation but hampered by a 15% decline in Biologics and Drug Delivery due to non-recurring partner orders. Management lowered FY26 revenue guidance to $48M-$52M, shifting focus toward clinical capacity and R&D for focused ultrasound and robotics platforms.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: ClearPoint Neuro(CLPT) the Revenue is 10.88 M (+18.07%), Miss estimate;the EBIT is -10.24 M (-80.35%), Miss estimate;the EPS is -0.38 (-80.95%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.01B18.07%
0.01B38.18%
-0.00B20.11%
EBITMiss expectations
-0.01B80.35%
-0.01B30.28%
-0.00B50.07%
EPSMiss expectations
-0.3880.95%
-0.286736.51%
-0.093344.44%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf